You are hereNovember 10, 2011
Reprogramming Stem Cells to a More Basic Form Results in More Effective Transplant, Study Shows
"Stem cell differentiation and transplantation has been shown to improve function in conditions including degenerative diseases and blood supply disorders," said Dr Chan. "However, the survival rate of transplanted cells in patients limits their overall effectiveness, which is a barrier to clinical use."
To overcome this issue Dr Chan’s team explored de-differentiation, a process that reverts specialized, differentiated cells back to a more primitive cell. The team focused their research on multipotent stem cells, (MSCs) which can be altered into a variety of cell types through differentiation. Bone marrow MSCs have the potential to differentiate into each of the three basic types of lineage cells which form bone (osteocytes), cartilage (chondrocytes) and fat tissue (adipocytes).
The team first differentiated bone marrow MSCs towards a neuronal lineage, but then removed the differentiation conditions, allowing the cell to revert back to a form with more basic cellular characteristics.
Following this process the team recorded increased cell survival rates following transplants. In an animal model de-differentiated cells were found to be more effective in improving cognitive functions and in aiding recovery from strokes, compared to un-manipulated stem cells both in living specimens and in laboratory experiments.
The results confirm that de-differentiation is a workable technique for reengineering cells to an earlier, more primitive state but reprogrammed to have increased cell survival rates and therefore their potential for clinical use.
"The finding that MSCs can be reprogrammed to have enhanced survival and therapeutic efficacy in an animal model with potential application to patients is extremely exciting as it may provide a novel and clinically practical method to overcome low cell survival in cellbased therapy," concluded Dr Chan. "We are currently exploring other beneficial properties of the reprogrammed MSCs for other therapeutic applications."
"Many investigators have speculated that differentiation should improve the utility of stem cells for transplantation, but how far to differentiate the cells for the best outcome is a difficult question. Dr Chan’s team have helped provide an answer by educating mesenchymal stem cells by pre-differentiating to the desired lineage before de-differentiation, making MSCs easier to manipulate and implant,” said Dr Mark Pittenger, STEM CELLS Associate Editor.
“Interesting questions still remain for future work such as which factors are expressed in the pre-differentiated stem cells that persist upon de-differentiation and can the de-differentiated cells be frozen for future use?”
This paper is published in STEM CELLS. Media Wishing to request a copy should contact Lifesciencenews@wiley.com or phone +44 (0)1243 770 375
Full Citation: Liu, Yang; Jiang, Xiaohua; Zhang, Xiaohu; Chen, Rui; Sun, Tingting; Fok, Kin Lam; Dong, Jianda; Tsang, Lai Ling; Yi, Shaoqiong; Ruan, Yechun; Guo, Jinghui; Yu, Mei Kuen; Tian, Yue; Chung, Yiu Wa; Yang, Mo; Xu, Wenming; Chung, Chin Man; Li, Tingyu; Chan, Hsiao, “Dedifferentiation-reprogrammed mesenchymal stem cells with improved therapeutic potential”, STEM CELLS, Wiley-Blackwell, October 2011, DOI: 10.1002/stem.764
Paper URL: http://doi.wiley.com/10.1002/stem.764
Contact the Author: Dr Chan can be contacted via Ms Amy Tsu, Communication Office, Chinese University of Hong Kong, firstname.lastname@example.org
About STEM CELLS: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research.
For more information, please visit: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1549-4918
STEM CELLS is co-published by AlphaMed Press and Wiley-Blackwell.
About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA and Belfast, United Kingdom publishes two internationally renowned peer-reviewed journals: STEM CELLS®, now in its 29th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (www.TheOncologist.com), also a monthly peer-reviewed publication, is in its 16th year and is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. Both journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. In January 2012, AlphaMed Press will launch a new peer-reviewed journal, STEM CELLS Translational Medicine that will hasten the clinical applications of stem cell therapies.
Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world’s leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or our new online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world’s most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.